Early postoperative seizures in liver and kidney recipients

Background. Transplantation is presently the only treatment for end-stage liver and kidney failure. Up to 42% of liver transplant recipients and up to 30% of kidney transplant recipients have neurological complications from the transplantation. Acute symptomatic seizures (ACS) occupy an important place in the structure of early postoperative neurological complications. Verification of the causes of seizures and management of the risk of relapse is presently a critical task.

Objective: to review recent advances in ACS assessment, prevalence, and treatment approaches in liver and kidney transplant recipients.

Materials and methods. The causes of ACS after liver and kidney transplant are diverse. Nonspecific causes of seizures such as dysmetabolic and volemic changes associated with transplantation are widely known. There are also specific syndromes associated with seizures in liver and kidney recipients, such as posterior reversible leukoencephalopathy syndrome, neurotoxicity of calcineurin inhibitors, hyponatremia in the final stage of liver failure, hypocalcemia in kidney recipients, etc. Diagnosis is made based on general rules, and treatment depends on the identified causes of seizures. Management of acute symptomatic seizures involves prescribing anticonvulsants according to the risk of seizure recurrence; immunosuppression is converted when neurotoxicity is identified. Results. The diagnostic algorithm, and often the treatment strategies, in ACS cases in liver and kidney recipients, are not clearly defined.

Conclusion. Due to the multiple causes of ACS, there are differences in treatment tactics. Further accumulation and generalization of ACS outcome data will help in creating a convenient algorithm for rapid identification of the cause and the most effective treatment tactics.

1. Gautier SV, Tsiroulnikova OM, Moysyuk YG, Akhaladze DG, Tsiroulnikova IE, Silina OV et al. Liver transplantation in children: six-year experience analysis. Russian Journal of Transplantology and Artificial Organs. 2014; 16 (3): 54–62. [In Russ, English abstract]. https://doi.org/10.15825/1995-1191-2014-3-54-62.

2. Dutkowski P, Linecker M, DeOliveira ML, Müllhaupt B, Clavien P-A. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015; 148 (2): 307–323. doi: 10.1053/j.gastro.2014.08.045.

3. Kumar SS, Mashour GA, Picton P. Neurologic Considerations and Complications Related to Liver Transplantation. Anesthesiology. 2018; 128 (5): 1008–1014. doi: 10.1097/ALN.0000000000002148.

4. Derle E, Kibaroğlu S, Öcal R et al. Seizure as a neurologic complication after liver transplant. Exp Clin Transplant Off J Middle East Soc Organ Transplant. 2015; 13 Suppl 1: 323–326. doi: 10.6002/ect.mesot2014.p176.

5. Patchell RA. Neurological complications of organ transplantation. Ann Neurol. 1994; 36 (5): 688–703. doi: 10.1002/ana.410360503.

6. Menegaux F, Keeffe EB, Andrews BT et al. Neurological complications of liver transplantation in adult versus pediatric patients. Transplantation. 1994; 58 (4): 447–450. doi: 10.1097/00007890-199408270-00010.

7. Lee B, Min NH, Ham SY, Na S, Kim J. Non-Convulsive Status Epilepticus following Liver Transplantation. Korean J Crit Care Med. 2016; 31 (1): 49–53. doi: 10.4266/kjccm.2016.31.1.49.

8. Beghi E, Carpio A, Forsgren L et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51 (4): 671–675. doi: 10.1111/j.1528-1167.2009.02285.x.

9. Fisher RS, Acevedo C, Arzimanoglou A et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 2014; 55 (4): 475–482. doi: 10.1111/epi.12550.

10. Ameres M, Melter M, Zant R, Schilling S, Geis T. Liver transplantation during infancy: No increased rate of neurological complications. Pediatr Transplant. 2018; 22 (8): e13304. doi: 10.1111/petr.13304.

11. Gungor S, Kilic B, Arslan M, Selimoglu MA, Karabiber H, Yilmaz S. Early and late neurological complications of liver transplantation in pediatric patients. Pediatr Transplant. 2017; 21 (3). doi: 10.1111/petr.12872.

12. Lee JJ, Lim S, Lee YS et al. Myoclonic movement after general anesthesia: A case report and review of the literature. Medicine (Baltimore). 2018; 97 (12): e0141. doi: 10.1097/MD.0000000000010141.

13. Nartailakov MA, Salimgaraev IZ, Panteleev VS et al. Refeeding Syndrome in Surgical Patients. A Clinical Case Analysis. Creative surgery and oncology. 2019; 9 (2): 118–124. [In Russ, English abstract]. https://doi.org/10.24060/2076-3093-2019-9-2-118-124.

14. Toxins and Drugs Reported to Induce Seizures. Epilepsy Foundation. Accessed April 15, 2021. https://www.epilepsy.com/learn/professionals/resource-library/tables/toxins-and-drugs-reported-induce-seizures.

15. Cruz RJ, DiMartini A, Akhavanheidari M et al. Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2012; 12 (8): 2228–2236. doi: 10.1111/j.1600-6143.2012.04048.x.

16. Fernandez D, El-Azzabi T, Jain V et al. Neurologic Problems After Pediatric Liver Transplantation and Combined Liver and Bowel Transplantations: A Single Tertiary Centre Experience. Transplantation. 2010; 90: 319–324. doi: 10.1097/TP.0b013e3181e5b7fc.

17. Lunardi N, Saraceni E, Boccagni P et al. Posterior reversible encephalopathy syndrome in the Intensive Care Unit after liver transplant: a comparison of our experience with the existing literature. Minerva Anestesiol. 2012; 78 (7): 847–850.

18. Dohgu S, Yamauchi A, Nakagawa S et al. Nitric oxide mediates cyclosporine-induced impairment of the bloodbrain barrier in cocultures of mouse brain endothelial cells and rat astrocytes. Eur J Pharmacol. 2004; 505 (1–3): 51–59. doi: 10.1016/j.ejphar.2004.10.027.

19. Chen H, Albertson TE, Olson KR. Treatment of druginduced seizures. Br J Clin Pharmacol. 2016; 81 (3): 412–419. doi: 10.1111/bcp.12720.

20. Rudakova IG, Belova IA, Kel NV, Alakova MV. Sudorogi obuslovlennye vodnoelectrolitnym disbalansom i epilepsia. Problemy diagnostiki i terapii. Nevroligiya. Neiropsihiatriya. Psihosomatica. 2014; (S1): 45–47. [In Russ, English abstract]. doi.org/10.14412/2074-2711-2014-1S-45-47.

21. Abbasoglu O, Goldstein RM, Vodapally MS et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant. 1998; 12 (3): 263–269.

22. Cascales Campos P, Ramirez P, Gonzalez R et al. Central pontine and extrapontine myelinolysis: a rare and fatal complication after liver transplantation. Transplant Proc. 2011; 43 (6): 2237–2238. doi: 10.1016/j.transproceed.2011.06.052.

23. Kim B-S, Lee S-G, Hwang S et al. Neurologic complications in adult living donor liver transplant recipients. Clin Transplant. 2007; 21 (4): 544–547. doi: 10.1111/j.1399-0012.2007.00687.x.

24. Gaynor JJ, Moon JI, Kato T et al. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation. 2007; 84 (2): 155–165. doi: 10.1097/01.tp.0000269090.90068.0f.

25. Abdel Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol. 2009; 15 (21): 2561–2569. doi: 10.3748/wjg.15.2561.

26. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010; 9 (4): 425–437. doi: 10.1016/S1474-4422(10)70040-5.

27. Ozdemir F, Ince V, Baskiran A et al. Progressive Multifocal Leukoencephalopathy after Three Consecutive Liver Transplantations. Int J Organ Transplant Med. 2015; 6 (3): 126–130.

28. Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy: A 25- year retrospective cohort study. Neurol Neuroimmunol Neuroinflammation. 2019; 6 (6). doi: 10.1212/NXI.0000000000000618.

29. Zivković S. Neuroimaging and neurologic complications after organ transplantation. J Neuroimaging Off J Am Soc Neuroimaging. 2007; 17 (2): 110–123. doi: 10.1111/j.1552-6569.2007.00097.x.

30. Beloborodova NB, Ostrova IV. Sepsis-Associated Encephalopathy (Review). General Reanimatology. 2017; 13 (5): 121–139. [In Russ, English abstract]. doi: 10.15360/1813-9779-2017-5-121-139.

31. Sonneville R, Verdonk F, Rauturier C et al. Understanding brain dysfunction in sepsis. Ann Intensive Care. 2013; 3 (1): 15. doi: 10.1186/2110-5820-3-15.

32. Shepard PW, St. Louis EK. Seizure Treatment in Transplant Patients. Curr Treat Options Neurol. 2012; 14 (4): 332–347. doi: 10.1007/s11940-012-0180-y.

33. Ismail D, Green J, Bannerman B et al. Posterior Reversible Encephalopathy Syndrome (PRES) in Adult Multi-Visceral Transplant patients – Cambridge University Hospital experience. Transplantation. 2017; 101 (6S2): S137. doi: 10.1097/01.tp.0000521492.43465.8a.

34. Dzyadzko AM, Katin ML, Rummo OO et al. Central pontine myelinolysis after orthotopic liver transplantation (two case reports). Russian Journal of Transplantology and Artificial Organs. 2013; 15 (1): 89–95. [In Russ, English abstract]. https://doi.org/10.15825/1995-1191-2013-1-89-95.

35. Glass GA, Stankiewicz J, Mithoefer A, Freeman R, Bergethon PR. Levetiracetam for seizures after liver transplantation. Neurology. 2005; 64 (6): 1084–1085. doi: 10.1212/01.WNL.0000154598.03596.40.

36. Государственный реестр цен на жизненно необходимые и важнейшие лекарственные препараты. Accessed April 22, 2021. http://farmcom.info/site/reestr?TnnName=%EA%E5%EF%EF%F0%E0.

37. Государственный реестр лекарственных средств. Accessed April 22, 2021. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=33129c9c-850c4b0d-b9bf-fae2cfd5a55c&t=.

38. Wijdicks EF, Plevak DJ, Wiesner RH, Steers JL. Causes and outcome of seizures in liver transplant recipients. Neurology. 1996; 47 (6): 1523–1525. doi: 10.1212/wnl.47.6.1523.

39. Chabolla DR, Wszolek ZK. Pharmacologic management of seizures in organ transplant. Neurology. 2006; 67 (12 Suppl 4): S34–38. doi: 10.1212/wnl.67.12_suppl_4.s34.

40. Epilepsy Foundation. Accessed February 1, 2021. https://www.epilepsy.com/living-epilepsy/epilepsy-and/professional-health-care-providers/co-existing-disorders-69.

41. Balderramo D, Prieto J, Cárdenas A, Navasa M. Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation. Transpl Int Off J Eur Soc Organ Transplant. 2011; 24 (8): 812–819. doi: 10.1111/j.1432-2277.2011.01280.x.

42. Wu S-Y, Chen T-W, Feng A-C, Fan H-L, Hsieh C-B, Chung K-P. Comprehensive risk assessment for early neurologic complications after liver transplantation. World J Gastroenterol. 2016; 22 (24): 5548–5557. doi: 10.3748/wjg.v22.i24.5548.

43. Sawhney H, Gill SS. Renal transplant recipient seizure practical management. World J Nephrol. 2020; 9 (1): 1–8. doi: 10.5527/wjn.v9.i1.1.

44. Pochineni V, Rondon-Berrios H. Electrolyte and AcidBase Disorders in the Renal Transplant Recipient. Front Med. 2018; 5. doi: 10.3389/fmed.2018.00261.

45. Meena P, Bhargava V, Rana D, Bhalla A, Gupta A. An Approach to Neurological Disorders in a Kidney Transplant Recipient. Kidney 360. 2020; 1 (8): 837–844. doi: 10.34067/KID.0002052020.

46. Barras P, Siclari F, Hügli O, Rossetti AO, Lamy O, Novy J. A potential role of hypophosphatemia for diagnosing convulsive seizures: A case-control study. Epilepsia. 2019; 60 (8): 1580–1585. doi: 10.1111/epi.16090.

47. Giussani A, Ardissino G, Belingheri M et al. Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases. Pediatr Transplant. 2016; 20 (1): 68–71. doi: 10.1111/petr.12640.

48. Medeni SS, Namdaroglu S, Cetintepe T et al. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematol Rep. 2018; 10 (3). doi: 10.4081/hr.2018.7553.

49. Haughey D, Narsipur SS. Posterior Reversible Encephalopathy Syndrome After Renal Transplant: A Simple Solution for a Complicated Patient. Case Rep Nephrol Dial. 2014; 5 (1): 20–25. doi: 10.1159/000366554.

50. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001; 77 (903): 24–28. doi: 10.1136/pmj.77.903.24.

51. Bhandari B, Komanduri S. Dialysis Disequilibrium Syndrome. In: StatPearls. StatPearls Publishing; 2021. Accessed April 16, 2021. http://www.ncbi.nlm.nih.gov/books/NBK559018/.

52. Uremic Encephalopathy: Practice Essentials, Pathophysiology, Epidemiology. Published online April 3, 2021. Accessed April 22, 2021. https://emedicine.medscape.com/article/239191-overview.

53. Uremic Encephalopathy. Epilepsy Foundation. Accessed April 22, 2021. https://www.epilepsy.com/living-epilepsy/epilepsy-and/professional-health-care-providers/co-existing-disorders/renal-disorders/uremic-encephalopathy.

54. Doorenbos CJ, Bosma RJ, Lamberts PJ. Use of urea containing dialysate to avoid disequilibrium syndrome, enabling intensive dialysis treatment of a diabetic patient with renal failure and severe metformin induced lactic acidosis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc. 2001; 16 (6): 1303– 1304. doi: 10.1093/ndt/16.6.1303.

55. Mistry K. Dialysis disequilibrium syndrome prevention and management. Int J Nephrol Renov Dis. 2019; 12: 69–77. doi: 10.2147/IJNRD.S165925.

56. Hughes JR. Correlations between EEG and chemical changes in uremia. Electroencephalogr Clin Neurophysiol. 1980; 48 (5): 583–594. doi: 10.1016/0013-4694(80)90293-x.

57. Gadewar P, Acharya S, Khairkar P, Shukla S, Mahajan SN. Dynamics of electroencephalogram (EEG) in different stages of chronic kidney disease. J Clin Diagn Res JCDR. 2015; 9 (3): OC25–27. doi: 10.7860/JCDR/2015/11257.5705.

58. Hamiwka LD, Midgley JP, Hamiwka LA. Seizures in children after kidney transplantation: has the risk changed and can we predict who is at greatest risk? Pediatr Transplant. 2008; 12 (5): 527–530. doi: 10.1111/j.1399-3046.2007.00813.x.

59. Nardone R, Brigo F, Trinka E. Acute Symptomatic Seizures Caused by Electrolyte Disturbances. J Clin Neurol Seoul Korea. 2016; 12 (1): 21–33. doi: 10.3988/jcn.2016.12.1.21.